MEDIVISION : and MTL Transaction Closing

MediVision Medical Imaging Ltd. ?+(972) 4-989-4884 ?+(972) 4-989-4883

? 26 Sweden St. Haifa, Israel 34980

? noam@medivision.co.il

Haifa, Israel, June 18th, 2013 - MediVision Medical Imaging Ltd. (the "Company", EuroNext: MEDV1) reports hereby, that following the execution of the Share Purchase Agreement (the "Agreement") dated January 16th 2013 (as detailed in the Company's press release dated January 22nd, 2013; and in Section 7 to the notice of the Company's General Meeting of Shareholders, convened on April 25th

2013), the parties to the Agreement have consummated the closing of the transactions underlying such Agreement, following the fulfillment of all closing conditions as detailed therein.

Following the closing, the Company has completed the merger into the Company's business of MTL Print Ltd ("MTL"), an Israeli private company, by way of acquisition of MTL's entire share capital (thus becoming a wholly owned subsidiary of the Company), in consideration for the issuance to the MTL shareholders and option-holders, of Company shares and/or options representing approximately 65% of the Company's post-closing issued share capital on a fully diluted basis. Corresponding changes have also come into effect to the Company's Articles of Association, board of directors and management (as detailed in the Company's press release dated April 25th, 2013 regarding the results of the Company's General Meeting of Shareholders). MTL is engaged in various activities in the field of R&D and manufacturing of capital equipment in the field of digital wide format printers.

1

This Report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of the Management of the Company as well as assumptions made by and
information currently available to the Management of the Company. Such statements reflect the current views of the Company wi th respect to future events, the outcome of which is subject to certain risks including but not limited to as listed below and other factors, which may be outside of the Company's control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results of outcomes may vary materially from those described herein as projected, anticipated, believed, estimated, expected or intended . Such abovementioned risks include but are not limited to: 1. Failure to consummate the proposed Transaction; 2. Uncertain market acceptance of Company products - The Company's future growth and profitability will depend, in large part, on the acceptance by the market of the Company's existing and proposed products. This acceptance will be substant ially dependent on educating the market as to full capabilities, distinctive characteristics, perceived benefits and efficacy of the Company's existing and proposed products. In addition, the future suc cess of the Company's products will depend on their acceptance by customers and on such customers' willingness and ability to purchase such products. There can be no assurance that the Company's products will recei ve the necessary market acceptance. Failure of the Company's existing and/or proposed products to gain market acceptance could have a material adverse effect on the Company's business, financial condition and results of operations. 3. Financial Requirements - The implementation of the Company's plans underlying the Transaction requires additional funding,. There is no certainty that the required funds will be available to the Company at all or upon terms acceptable to the company.

MediVision Press Release 20130618 - MTL Closing

distributed by